⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514389 | 0.81 | — | — | |
| SCHEMBL966398 | 0.79 | — | — | |
| SCHEMBL423983 | 0.78 | HDAC3 (0.30) | — | |
| SCHEMBL31543507 | 0.77 | — | — | |
| SCHEMBL26916483 | 0.77 | — | — | |
| SCHEMBL31664981 | 0.77 | — | — | |
| SCHEMBL27679459 | 0.77 | — | — | |
| SCHEMBL14380070 | 0.77 | — | — | |
| SCHEMBL24716797 | 0.77 | HDAC3 (0.33) | — | |
| SCHEMBL29285032 | 0.77 | HDAC3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119421882-A | FGFR2 inhibitor compounds | 伊莱利利公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-8557849-B2 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2013-10-15 | — | — | US | disclosed |
| EP-2257168-B1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER IP GMBH (DE) | 2013-06-05 | — | — | EP | disclosed |
| CN-101977503-A | Fungicide hydroximoyl-tetrazole derivatives | FUNGICIDE HYDROXIMOYL TETRAZOLE DERIVATIVES | 2011-02-16 | — | — | CN | disclosed |
| US-20110015236-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2257168-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | Bayer CropScience AG (DE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115556-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-09-24 | — | — | WO | disclosed |